Sugi Predict

Sugi Predict / Compounds / SCHEMBL4185751

SCHEMBL4185751

SCHEMBL4185751

O=[N+]([O-])c1ccc(-n2cccn2)nc1

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.54
▸ MAPT P10636 4/20 0.53
▸ ALDH1A1 P00352 6/20 0.51
▸ ALOX12 P18054 1/20 0.51
▸ NPSR1 Q6W5P4 1/20 0.51
▸ KMT2A Q03164 4/20 0.50
▸ MEN1 O00255 3/20 0.50
▸ ATM Q13315 1/20 0.50
▸ CYP1A2 P05177 1/20 0.49
▸ CYP2C9 P11712 1/20 0.49
▸ HPGD P15428 1/20 0.49
▸ CHRNA7 P36544 1/20 0.45
▸ KDM4E B2RXH2 4/20 0.44
▸ NPBWR1 P48145 1/20 0.44
▸ MCHR1 Q99705 1/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ RXFP1 Q9HBX9 1/20 0.43
▸ SLC2A1 P11166 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30522724 1.00 LMNA (0.54) LMNAMAPTALDH1A1ALOX12NPSR1
SCHEMBL27929641 0.77 MAPT (0.58) LMNAMAPTALDH1A1ALOX12NPSR1
SCHEMBL4449726 0.77 NOTUM (0.55) LMNAMAPTALDH1A1KMT2AMEN1
SCHEMBL9113748 0.75 MAPT (0.53) LMNAMAPTALDH1A1ALOX12NPSR1
SCHEMBL25256939 0.74 MAPT (0.55) LMNAMAPTALDH1A1ALOX12NPSR1
SCHEMBL4548418 0.74 MAPT (0.51) LMNAMAPTALDH1A1ALOX12NPSR1
SCHEMBL11901316 0.74 MAPT (0.51) LMNAMAPTALDH1A1ALOX12NPSR1
SCHEMBL1163827 0.72 KCNJ1 (0.55) LMNAMAPTALDH1A1ALOX12NPSR1
SCHEMBL20577072 0.72 CHRNA7 (0.54) LMNAALDH1A1KMT2AMEN1CYP1A2
SCHEMBL4876756 0.72 MAPT (0.53) LMNAMAPTALDH1A1ALOX12NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4574150-A2 A MAGL INHIBITOR H. Lundbeck A/S (DK) 2025-06-25 — — EP disclosed
EP-4244208-B1 A MAGL INHIBITOR H LUNDBECK AS (DK) 2025-04-02 — — EP disclosed
US-20240018120-A1 MAGL INHIBITORS H. LUNDBECK A/S (DK) 2024-01-18 — — US disclosed
US-20240018120-A1 MAGL INHIBITORS H. LUNDBECK A/S (DK) 2024-01-18 — — US disclosed
US-11724982-B2 Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2023-08-15 — — US disclosed
US-11724982-B2 Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2023-08-15 — — US disclosed
CN-116547274-A MAGL inhibitors H.隆德贝克有限公司 2023-08-04 — — CN disclosed
US-11434222-B2 MAGL inhibitors H. LUNDBECK A/S (DK) 2022-09-06 — — US disclosed
US-20220153721-A1 MAGL INHIBITORS H. LUNDBECK A/S (DK) 2022-05-19 — — US disclosed
WO-2022101412-A1 A MAGL INHIBITOR H. LUNDBECK A/S (DK) 2022-05-19 — — WO disclosed
US-8895585-B2 Nicotinamide derivative or salt thereof FUJIFILM CORPORATION (JP) 2014-11-25 — — US disclosed
US-8895585-B2 Nicotinamide derivative or salt thereof FUJIFILM CORPORATION (JP) 2014-11-25 — — US disclosed
US-8809371-B2 — — 2014-08-19 — — US disclosed
US-8809371-B2 — — 2014-08-19 — — US disclosed
US-8772320-B2 — — 2014-07-08 — — US disclosed
US-20130116430-A1 NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF FUJIFILM CORPORATION (JP) 2013-05-09 — — US disclosed
US-20130116430-A1 NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF FUJIFILM CORPORATION (JP) 2013-05-09 — — US disclosed
EP-2589592-A1 NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF FUJIFILM Corporation (JP) 2013-05-08 — — EP disclosed
US-20090143440-A1 Pyrazoles Useful in the Treatment of Inflammation BIOLIPOX AB (SE) 2009-06-04 — — US disclosed
EP-0205021-A2 5-Amino-4-cyano-1-pyridyl pyrazoles BAYER AG (DE) 1986-12-17 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11434222-B2 MAGL inhibitors MAG, MAGI3, MAGT1 LMNA 3061/4885MAPT 951/4885ALDH1A1 2747/4885
US-20130116430-A1 NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF SYK, CD38, BTK LMNA 3649/4885MAPT 4186/4885ALDH1A1 1638/4885
US-20240018120-A1 MAGL INHIBITORS MAG, MAGI3, MAGT1 LMNA 3061/4885MAPT 951/4885ALDH1A1 2747/4885
US-20090143440-A1 Pyrazoles Useful in the Treatment of Inflammation ALOX15, ALOX12, ALOX15B LMNA 1666/4885MAPT 4581/4885ALDH1A1 654/4885
US-11724982-B2 Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration AHR, AFF2, AFF4 LMNA 1773/4885MAPT 3670/4885ALDH1A1 778/4885
US-20220153721-A1 MAGL INHIBITORS MAG, MAGI3, MAGT1 LMNA 3061/4885MAPT 951/4885ALDH1A1 2747/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.